Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Design Therapeutics, Inc. (DSGN)

Design Therapeutics Q2 net loss widens to $20.2 million; FECD data delayed to 2027

Negative Impact 3 of 5 earnings Written later

Design Therapeutics reported a second quarter 2026 net loss of $20.2 million, up from $19.1 million a year earlier, with no revenue reported in the filing. The company ended the quarter with $207.4 million in cash and investment securities and said it is modifying the RESTORE-FA trial after four-week data, with 12-week data expected in the first quarter of 2027.

Key points

  • Q2 2026 net loss was $20.2 million versus $19.1 million in Q2 2025; R&D expenses were $16.4 million and G&A expenses were $5.8 million.
  • Cash, cash equivalents and investment securities were $207.4 million at June 30, 2026, down from $219.8 million at December 31, 2025.
  • Data from the DT-168 Phase 2 trial in Fuchs endothelial corneal dystrophy is now expected in 2027 due to a delay in drug supply.
  • Dosing began in the DT-818 Phase 1 trial in myotonic dystrophy type 1; data are expected in 2027.

The filing

CompanyDesign Therapeutics, Inc. (DSGN)
Form8-K, current report
Filed with the SECAug 3, 2026, 8:03 AM ET
Accession number0001193125-26-329570

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.